SobrietyGuard: Clinically Supported Anti-Alcohol Medication
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.14 | $214.24 (0%) | 🛒 Add to cart |
| 60 | $6.76 | $428.49 $405.46 (5%) | 🛒 Add to cart |
| 90 | $6.62
Best per pill | $642.73 $595.68 (7%) | 🛒 Add to cart |
Synonyms | |||
SobrietyGuard represents a significant advancement in pharmacological support for individuals committed to reducing or eliminating alcohol consumption. This prescription medication contains naltrexone hydrochloride as its active ingredient, specifically formulated to support alcohol abstinence by modulating neurotransmitter activity in the brain’s reward pathways. Developed through extensive clinical research, SobrietyGuard operates by competitively binding to opioid receptors, thereby reducing the pleasurable effects associated with alcohol consumption. Medical supervision is essential throughout treatment to ensure optimal dosing and monitor patient response.
Features
- Contains 50mg naltrexone hydrochloride per tablet
- Extended-release formulation for consistent 24-hour coverage
- Manufactured in FDA-approved facilities following cGMP standards
- Child-resistant packaging with moisture-protective blister packs
- Includes comprehensive patient information materials
- Third-party tested for purity and potency verification
Benefits
- Reduces alcohol cravings through targeted neurological mechanisms
- Supports long-term abstinence by diminishing alcohol’s reinforcing effects
- Compatible with comprehensive addiction treatment programs
- Demonstrated efficacy in multiple randomized controlled trials
- Provides physiological support while patients develop behavioral coping strategies
- May help reduce relapse frequency in alcohol-dependent individuals
Common use
SobrietyGuard is indicated for the maintenance of alcohol abstinence in patients with alcohol dependence who have undergone initial detoxification and are participating in a comprehensive treatment program that includes psychosocial support. The medication is typically prescribed as part of a multifaceted approach to alcohol use disorder management, combining pharmacological intervention with counseling, behavioral therapies, and support group participation. Treatment is generally initiated after the patient has achieved alcohol-free status for at least 3-7 days to minimize the risk of precipitated withdrawal symptoms.
Dosage and direction
The recommended dosage is one 50mg tablet administered orally once daily, with or without food. Treatment should be initiated under medical supervision, typically beginning with a thorough assessment of liver function. Patients should be advised to take the medication at approximately the same time each day to maintain consistent plasma concentrations. The tablet should be swallowed whole and not crushed, chewed, or dissolved. Dosage adjustments may be necessary based on individual tolerance and treatment response, though the 50mg daily dose has demonstrated optimal efficacy in clinical studies for most patients.
Precautions
Liver function tests should be conducted before initiation and periodically during treatment, as naltrexone may cause dose-related hepatocellular injury. Patients should be advised that SobrietyGuard does not eliminate intoxication effects and should not be viewed as protection against alcohol consumption. Caution is advised when operating machinery or driving until the patient’s response to treatment is established. Patients should carry identification noting their use of naltrexone in case emergency medical treatment is required. Healthcare providers should monitor for depression or suicidal ideation, particularly during early treatment phases.
Contraindications
SobrietyGuard is contraindicated in patients with acute hepatitis or liver failure, those currently dependent on opioids (including those undergoing acute opioid withdrawal), patients with hypersensitivity to naltrexone or any product components, and individuals who have failed the naloxone challenge test or have positive urine screen for opioids. Concurrent use with opioid analgesics is contraindicated due to potentially diminished analgesic efficacy and risk of acute opioid withdrawal.
Possible side effects
Common adverse reactions (occurring in >5% of patients) include nausea (10%), headache (7%), dizziness (6%), fatigue (5%), and insomnia (5%). Less frequent side effects may include anxiety, nervousness, abdominal cramps, joint pain, and decreased energy. Approximately 10% of patients discontinue treatment due to adverse events, primarily during the first month of therapy. Hepatotoxicity, though rare at recommended doses, represents the most serious potential adverse effect requiring regular monitoring.
Drug interaction
SobrietyGuard may precipitate acute withdrawal in opioid-dependent patients. Concurrent use with opioid medications may diminish their analgesic efficacy and potentially lead to overdose if higher doses are consumed. Caution is advised with hepatotoxic drugs including acetaminophen, certain anticonvulsants, and antifungal medications. Naltrexone may affect the metabolism of drugs primarily processed through hepatic pathways. Healthcare providers should conduct comprehensive medication reviews before initiation and during treatment.
Missed dose
If a dose is missed, patients should take it as soon as remembered unless it is接近 time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic effects, so patients should establish routines to support adherence.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Symptoms may include nausea, abdominal pain, dizziness, and laboratory evidence of hepatic dysfunction. There is no specific antidote for naltrexone overdose; treatment should be supportive and symptomatic. Hemodialysis is not expected to enhance elimination significantly due to naltrexone’s extensive tissue distribution and protein binding. Management should include comprehensive metabolic monitoring, particularly hepatic function assessment.
Storage
Store at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets appear discolored. Properly dispose of any unused medication after the expiration date printed on the packaging.
Disclaimer
SobrietyGuard is a prescription medication that should be used only under appropriate medical supervision. This information does not replace professional medical advice, diagnosis, or treatment. Always consult your healthcare provider for personalized guidance regarding alcohol use disorder treatment. Individual results may vary, and successful outcomes typically require comprehensive treatment including behavioral therapy and support systems.
Reviews
Clinical studies demonstrate that 65% of patients taking naltrexone maintained complete abstinence throughout 12-week trials compared to 35% receiving placebo. Patients report significantly reduced craving intensity within the first two weeks of treatment. Healthcare providers note improved treatment engagement and better outcomes when medication is combined with psychosocial support. Long-term follow-up studies indicate sustained benefits for up to one year with continuous treatment.